The underlying mechanisms of this additional effect of quinacrine on HCQ therapy in CLE have been poorly studied, although it was recently reported that quinacrine, but not HCQ, may affect TNFα release from PBMC of DM and CLE patients (20). Here, TNF is linked to dermatomyositis.